Pipeline
Rise Therapeutics is developing a pipeline of Immunobiotic therapies to treat a wide range of clinical indications. Leveraging its discovery capabilities, Rise has identified several unique microbiome-related pathways that potentially have therapeutic relevance. With our strong product development focus, Rise plans to establish clinical proof-of-concept for its pipeline in a wide range of indications including autoimmunity, inflammation, cancer, and infectious disease.
R-2487
R-2487 is Rise Therapeutics’ most advanced program that is nearing clinical proof-of-concept studies. Based upon Rise’s core TPX platform technology that enables delivery of oral biological therapies, R-2487 is a probiotic encapsulated biologic that has the unique ability to induce specific populations of T regulatory cells. R-2487 has a unique mechanism of action by which it can reset T regulatory deficiencies and reduce specific inflammatory cytokines that contribute to autoimmune disease.
R-3750
R-3750 is a unique enhanced probiotic therapy which is based upon targeting a key microbiome regulatory pathway the reduces inflammatory processes. This program is being developed for the treatment of inflammatory bowel disease (IBD). R-3750 works by engaging a specific immune receptor expressed on dendritic cells lining the gut epithelial layer inducing colonic T regulatory cells and immune homeostasis. R-3750 has the ability to improve the integrity of the gut membrane barrier and reestablish a more normal microbiome makeup. R-3750 is an oral therapy that has the potential to treat the underlying basis of GI-associated inflammatory disease.
R-5780
R-5780 is an orally delivered immune oncology drug candidate that engages specific microbiome associated immune pathways for the treatment of cancer. As a probiotic encapsulated biological therapy, R-5780 has demonstrated pronounced anti-tumor activity. This drug candidate builds upon the growing understanding of how certain commensals can help promote efficacy of immune oncology drugs. Rather than building a product around natural commensals which can be difficult to understand mechanism of action, R-5780 is a targeted drug product that engaged selective immune pathways that can support a robust anti-tumor T cell response. This revolutionary immune oncology drug candidate is one of the first of its kind in the context of mechanism of action and potential for success in the context of cancer treatment.
R-4329
R-4329, an orally administered, probiotic encapsulated targeted biological therapy, localizes to the gastrointestinal space and is being develop for prevention and treatment of C. difficile infection. R-4329 generates unique peptidoglycan fragments that activate critical host immune pathways. The mechanism of action of this drug confines pathogens to the intestinal lumen by enhancing epithelial barrier integrity, ultimately protecting the host from enteric pathogens. The unique anti-infective properties suggest R-4329 could be used as a front-line preventative and/or treatment for a wide variety of enteric infections, including C. difficile.